News

MediGene Completes the Transfer of Eligard® Rights for EU Countries to Astellas

SHOW RELEASE

MediGene and Pierre Fabre Sign Agreement for the Commercialization of Veregen® in Mexico, Central America, Venezuela and Colombia

SHOW RELEASE

MediGene Adds Romania and Bulgaria to Existing Partnership Agreement with Meditrina for the Commercialization of Veregen®

SHOW RELEASE

MediGene Concludes an Agreement with Laboratoires Expanscience for the Commercialization of Veregen® in France

SHOW RELEASE

MediGene AG Reports Nine Months 2010 Results: Continuing Increase in Revenue, Net Loss Cut by Half

SHOW RELEASE

MediGene announces corporate restructuring and aims to strengthen pipeline

SHOW RELEASE

MediGene Obtains Additional US Patent Protection

SHOW RELEASE

MediGene AG Reports Financial Results for First Six Months of 2010: Continuing Increase in Total Revenue, Significant Reduction of Loss

SHOW RELEASE

Change of date: 6-month 2010 financial report on August 5, 2010

SHOW RELEASE

MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties

SHOW RELEASE